On September 1, 2022 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, reported that members of IMV’s executive management team will be presenting at two investor conferences in September (Press release, IMV, SEP 1, 2022, View Source [SID1234618874]). Please find additional details on the conferences below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• H.C. Wainwright 24th Annual Global Investment Conference, New York City
Format: In-person presentation and one-on-one investor meetings
Speaker: Andrew Hall, Chief Executive Officer at IMV Inc.
Date: September 12, 2022
Time: 2:30 p.m. ET

Please contact your H.C. Wainwright representative for more information.

• Cantor Fitzgerald’s Oncology & HemOnc Conference, New York City
Format: Panel "Building I/O combinations: What are the Novel Ideas?" and one-on-one investor meetings
Speaker: Jeremy Graff, Ph.D., Chief Scientific Officer at IMV Inc.
Date: September 28, 2022
Time: 10:40 a.m. ET